

CAR-T cell therapy extended consent document for R/R DLBCL/PMBCL

Lead Organisation: NA-ATTC

Author: Haematology Team, The Newcastle Upon Tyne Hospital NHS Foundation Trust

Version Number: 2024-04-29

Finalisation Date: 18Dec25

End user rights:

This document is shared with permission for re-use to distribute, remix, adapt, and build upon the material in any medium or format for non-commercial purposes only, so long as the attributions listed below are given.

Attributions: The Newcastle Upon Tyne Hospital NHS Foundation Trust

This document is made available under a Creative Commons Attribution-NonCommercial 4.0 International License as described here: <https://creativecommons.org/licenses/by-nc/4.0/>

The information, materials and any opinions contained in this document are provided for general information and educational purposes only, are not intended to constitute legal, medical or other professional advice and should not be relied on or treated as a substitute for specific advice relevant to particular circumstances. Although we make all reasonable efforts to ensure the information is up to date, we make no representations, warranties or guarantees in that regard. In no event shall the creator(s) be liable for any direct, indirect, special, consequential or other claims, losses or damages that are related to the use or reliance whatsoever in the content of the document or any part thereof, except to the extent that such liability cannot be excluded by law. We do not seek to exclude or limit in any way our liability to the user for personal injury or death caused as a result of our negligence or seek to exclude or limit our liability for fraud or fraudulent misrepresentation by us.

We reserve the right to make changes and improvements to any information contained within this document, at any time and without notice. Where this document contains hyperlinks to other websites operated by parties not connected to us, such hyperlinks are provided for your reference only. We do not control such websites and are not responsible for their contents.

The inclusion of hyperlinks from this document or the website to such websites does not imply any endorsement of the material on such websites or any association with their operators. We accept no responsibility of any nature whatsoever for linked web sites or any information contained in them.

Continuation page.

CAR-T cell therapy extended consent document for R/R DLBCL/PMBCL

I give my consent for: autologous CAR-T cell therapy for relapsed DLBCL/PMBCL
(Infusion of your genetically modified T-cells after I have received chemotherapy)

- For relapsed/refractory diffuse large B-cell lymphoma
- For relapsed/refractory primary mediastinal B-cell lymphoma

Using

Axicabtagene ciloleucel (Axi-cel, Kite)

Patient sticker

1. I understand that the side effects of fludarabine/ cyclophosphamide chemotherapy include:
 - Sickness and vomiting
 - Sore mouth and diarrhoea
 - Hair loss
 - An increased risk of infection
2. I understand that after I have received chemotherapy I must follow the treatment plan and advice of doctors and nurses, including:
 - Having an infusion of CAR-T cells
 - Staying as an inpatient for at least 10-14 days from day of CAR-T cell infusion
 - Attending outpatient clinics after discharge weekly for 4-6 weeks
 - Contacting the CAR-T cell team or alert number to be admitted without delay if I become ill
 - I am not allowed to drive for 2 months
 - I am aware that I need to stay within a 2 hour distance from Freeman Hospital for the first 30 days after CAR-T cell infusion and that I need to have an appointed person with me at all times, who can assist me.
3. I understand that there are benefits and risks to having a transplant.

Concerning the **benefits**, it has been explained to me that:

- The benefit of having CAR-T cells is greater than the risk of having this therapy
- Having CAR-T cells will give me a better chance of being alive and well in two years' time than not having this therapy

Concerning the **risks**, it has been explained to me that:

- CAR-T cell therapy could result in my death through infection and complications related to CAR-T cell therapy (5% average risk)
- I understand that there is a very high chance that I will develop cytokine release syndrome leading to fevers, myalgia, headache, drop in blood pressure, fast heart beat and trouble with breathing. In most cases these symptoms are mild to moderate but in 10-15% of cases they can be severe and even life threatening.
- I understand that the treatment can commonly cause mild to moderate neurologic side effects including confusion and delirium, headache, problems with speaking and writing

and rarely more severe potentially life-threatening side effects including decrease in consciousness, seizures and coma.

- I understand that the risk of being admitted to an intensive care unit is around 20% mainly for following reasons:
 - to support blood pressure
 - to improve oxygen supply by non-invasive ventilation
 - There is a small chance that I might require to be sedated and intubated or require kidney support for a few days.
 - I understand that there is a risk that my disease could still come back
 - I understand that the treatment may increase the risk of developing another cancer later in life.
 - I understand that there is a small risk (<1%) that my genetically modified cells could develop into a T-cell lymphoma in the future
 - I understand that a proportion of patients will have prolonged reduction in blood counts and that I might require injections to support my white cell count and regular blood products.
 - I understand that depletion of normal B-lymphocytes might make me more susceptible to recurrent infections, which can be fatal and I might require prolonged regular immunoglobulin replacement.
 - I understand that I need to stay on prophylactic antibiotics and antivirals for a long period after the CAR-T cell therapy and that I will be re-vaccinated.
4. I understand that my treatment will be reported to national and international transplant registries but that my personal details will be kept confidential.
5. I understand that in a small proportion of patients the manufacturing companies are not able to produce a CAR-T product from the cells collected and therefore treatment might not be possible.
6. I understand that if my condition deteriorates significantly prior to the return of the manufactured CAR-T cells, that CAR-T treatment might not be possible.
7. I understand that my chance of achieving long-term remission following infusion of CAR-T cells is around in line with current trial and real world data.

Lymphoma/CAR-T Consultant receiving consent:

PRINT NAME: _____ SIGN: _____ DATE _____

Patient or person responsible for patient:

I have received sufficient information about CAR-T cell therapy and wish to proceed:

PRINT NAME: _____ SIGN: _____ DATE _____